logo
Plus   Neg
Share
Email

CEL-SCI Corp: The Leap From $0.80 To $8.00

pharma-032117_24jun19-lt.jpg

Shares of CEL-SCI Corporation (CVM), which have been hitting new highs, are up over 940 percent from their 52 week low of $0.82 recorded on August 7, 2018.

CEL-SCI is a biotechnology company involved in the research and development of immunotherapy products for the treatment of cancer, autoimmune and infectious diseases.

The Company's lead clinical program is Multikine, an immunotherapeutic agent that is being developed as a potential first-line neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck, and potentially, as a treatment for cervical dysplasia or peri-anal warts in HIV/HPV co-infected patients.

A phase III study of Multikine in head and neck cancer, which has enrolled 928 patients, is underway. It is the largest phase III study in the world for the treatment of head and neck cancer.

On March 29, 2019, an Independent Data Monitoring Committee (IDMC), which reviewed the data from the Company's pivotal phase III head and neck cancer study of Multikine, recommended that the trial be continued until the appropriate number of events have occurred.

The last patients in the trial were treated in September 2016, and CEL-SCI expects the final results of the trial to be reported soon.

Another investigational program of the Company is its LEAPS technology that is currently being developed as a therapeutic antigen-specific treatment for rheumatoid arthritis and is supported by grants from the National Institutes of Health.

Upon completion of preclinical and Investigational New Drug (IND) enabling studies for the antigen-specific LEAPS vaccine treatment of rheumatoid arthritis, CEL-SCI intends to file an IND application with the FDA.

On July 1, 2019, the Company is all set to join the broad-market Russell 3000 Index , and that provides an opportunity to better increase its visibility within the investment community.

As of this writing, CVM is up 7.60% at $8.64.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT